FDA Approval for Sanofi Drug Marks an Important First in Rare Disease

Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this rare enzyme deficiency.

The post FDA Approval for Sanofi Drug Marks an Important First in Rare Disease appeared first on MedCity News.

Leave a Reply

Your email address will not be published. Required fields are marked *